For Patients

?

Bladder Cancer Trials

Phase 2 Clinical Trial in Metastatic Bladder Cancer

Borealis-1™ is a company-sponsored, randomized, placebo-controlled Phase 2 trial of apatorsen in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer. Borealis-1 aims to evaluate the potential benefit of apatorsen in combination with standard of care first-line chemotherapy in patients with metastatic bladder cancer by measuring the treatments’ impact on survival.

FULLY ENROLLED: Learn more about the Borealis-1 Trial.

Phase 2 Clinical Trial in Metastatic Bladder Cancer

Borealis-2™ is an investigator-sponsored, randomized Phase 2 trial evaluating apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy. Borealis-2 is designed to evaluate the potential benefit of adding apatorsen to standard of care second-line chemotherapy by measuring the treatments’ impact on survival. The trial is sponsored by the Hoosier Oncology Group.

To see if you qualify, visit mytrialmatch.com or call 1-855-216-0159
NOW ENROLLING: Learn more about the Borealis-2 Trial.

Phase 1 Clinical Trial in Superficial or Non-Muscle Invasive Bladder Cancer

This investigator-initiated, open-label Phase 1 trial is designed to evaluate the potential benefit of apatorsen when directly infused into the bladder of patients with superficial or non-invasive bladder cancer. The trial is sponsored by the National Cancer Institute of Canada.

NOW ENROLLING: Learn more about the apatorsen Phase 1 Bladder Cancer Trial.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue